|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0768 SEK | -1.66% |
|
-11.52% | -52.30% |
| 07-02 | Malin Lundberg to Leave Cell Impact AB as CFO and Remain with the Company Until 30 September 2026 | CI |
| 07-02 | Cell Impact CFO to Step Down by September-end | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 71.35M | 76.81M | 47.26M | 37.32M | 5.57M | |||||
Other Revenues, Total | 10.45M | 14.72M | 401K | 598K | 116K | |||||
Total Revenues | 81.8M | 91.53M | 47.66M | 37.92M | 5.69M | |||||
Cost of Goods Sold, Total | 46.92M | 54.59M | 21.81M | 31.91M | 10.66M | |||||
Gross Profit | 34.88M | 36.94M | 25.85M | 6.01M | -4.97M | |||||
Selling General & Admin Expenses, Total | 103M | 124M | 120M | 62.27M | 46.96M | |||||
Depreciation & Amortization - (IS) | 10.19M | 16.38M | 23.66M | 31.27M | 72.89M | |||||
Other Operating Expenses | 47K | 630K | 1.64M | 11.5M | 3.1M | |||||
Other Operating Expenses, Total | 113M | 141M | 145M | 105M | 123M | |||||
Operating Income | -78.04M | -104M | -119M | -99.02M | -128M | |||||
Interest Expense, Total | -1.69M | -1.54M | -3.05M | -2.56M | -4.41M | |||||
Interest And Investment Income | - | 859K | 1.18M | 1.47M | 210K | |||||
Net Interest Expenses | -1.69M | -679K | -1.87M | -1.09M | -4.2M | |||||
Currency Exchange Gains (Loss) | - | 607K | - | -234K | -234K | |||||
Other Non Operating Income (Expenses) | -2K | -1K | -1K | -1K | 371K | |||||
EBT, Excl. Unusual Items | -79.73M | -104M | -121M | -100M | -132M | |||||
EBT, Incl. Unusual Items | -79.73M | -104M | -121M | -100M | -132M | |||||
Income Tax Expense | 122K | 70K | 38K | 85K | 5K | |||||
Earnings From Continuing Operations | -79.85M | -104M | -121M | -100M | -132M | |||||
Net Income to Company | -79.85M | -104M | -121M | -100M | -132M | |||||
Net Income - (IS) | -79.85M | -104M | -121M | -100M | -132M | |||||
Net Income to Common Incl Extra Items | -79.85M | -104M | -121M | -100M | -132M | |||||
Net Income to Common Excl. Extra Items | -79.85M | -104M | -121M | -100M | -132M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -13.49 | -13.76 | -11.07 | -1.62 | -0.78 | |||||
Basic EPS - Continuing Operations | -13.49 | -13.76 | -11.07 | -1.62 | -0.78 | |||||
Basic Weighted Average Shares Outstanding | 5.92M | 7.57M | 10.96M | 61.82M | 169M | |||||
Net EPS - Diluted | -13.49 | -13.76 | -11.07 | -1.62 | -0.78 | |||||
Diluted EPS - Continuing Operations | -13.49 | -13.76 | -11.07 | -1.62 | -0.78 | |||||
Diluted Weighted Average Shares Outstanding | 5.92M | 7.57M | 10.96M | 61.82M | 169M | |||||
Normalized Basic EPS | -8.42 | -8.6 | -6.92 | -1.01 | -0.49 | |||||
Normalized Diluted EPS | -8.42 | -8.6 | -6.92 | -1.01 | -0.49 | |||||
Supplemental Items | ||||||||||
EBITDA | -72.3M | -92.9M | -108M | -80.16M | -106M | |||||
EBITA | -77.92M | -104M | -119M | -98.67M | -127M | |||||
EBIT | -78.04M | -104M | -119M | -99.02M | -128M | |||||
EBITDAR | -70.93M | -90.88M | -107M | -79.63M | -105M | |||||
Total Revenues (As Reported) | 81.8M | 92.13M | 48.58M | 26.84M | 2.06M | |||||
Effective Tax Rate - (Ratio) | -0.15 | -0.07 | -0.03 | -0.08 | -0 | |||||
Total Current Taxes | 122K | 70K | 38K | 85K | 5K | |||||
Normalized Net Income | -49.83M | -65.09M | -75.85M | -62.72M | -82.49M | |||||
Interest on Long-Term Debt | 898K | 823K | 1.12M | 1.06M | 1.06M | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 989K | 1.59M | 3.07M | 3.13M | 3.51M | |||||
Net Rental Expense, Total | 1.37M | 2.02M | 733K | 525K | 250K | |||||
Imputed Operating Lease Interest Expense | 894K | 773K | 410K | 292K | 307K | |||||
Imputed Operating Lease Depreciation | 477K | 1.24M | 323K | 233K | -56.65K |
- Stock Market
- Stocks
- CI Stock
- Financials Cell Impact AB
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















